Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Adenocarcinoma clinical trials
Every US clinical trial registered for Esophageal Adenocarcinoma — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
44 US clinical trials · 27 currently recruiting
The research picture
Esophageal Adenocarcinoma has 44 registered US clinical trials, 27 of them open to new participants right now — about 61% of the total.
- 27
- recruiting participants now
- 61%
- of trials open to enrollment
- 2
- in Phase 3–4 (later-stage)
- 3
- top sponsor: Mayo Clinic
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
Midwest Biomedical Research Foundation
NCT00574327
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
University of Colorado, Denver
NCT05530343
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Mayo Clinic
NCT03961945
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
Case Comprehensive Cancer Center
NCT06687603
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
NCT06324357
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
University of Colorado, Denver
NCT05753748
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
Mayo Clinic
NCT06071845
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AstraZeneca
NCT06005493
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
AbbVie
NCT06628310
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT07432295
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium
NCT07284186
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune
NCT07021066
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Anwaar Saeed
NCT03539822
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
Roswell Park Cancer Institute
NCT04682158
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co.
NCT06266299
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
VA Office of Research and Development
NCT05563766
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT04114136
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Yale University
NCT07282912
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
University of Wisconsin, Madison
NCT04150640
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
NCT02366819
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
NCT04939051
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Weill Medical College of Cornell University
NCT06340711
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
Denver Health and Hospital Authority
NCT06532734
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06623396
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Memorial Sloan Kettering Cancer Center
NCT02962063
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology
NCT05945823
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
Weill Medical College of Cornell University
NCT02998268
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT04430738
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
National Cancer Institute (NCI)
NCT02521285
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
NCT04929392
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
NCT05480384
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
University of North Carolina, Chapel Hill
NCT02075905
Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
Memorial Sloan Kettering Cancer Center
NCT01970306
The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)
Columbia University
NCT05524844
Esophageal Cytology With FISH in Detecting Esophageal Cancer
OHSU Knight Cancer Institute
NCT02100189
Confocal Endomicroscopy for Barrett's Esophagus
Johns Hopkins University
NCT00487695
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma
University of Oklahoma
NCT03526328
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
Columbia University
NCT02513784
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
Seagen
NCT04499924
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
OHSU Knight Cancer Institute
NCT02890979
Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue
Mayo Clinic
NCT00909350
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 17 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Esophageal Adenocarcinoma Trial Landscape
ClinicalTrials.gov lists 44 US studies indexed under Esophageal Adenocarcinoma, and 27 of those are currently open to recruitment — roughly 61% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Esophageal Adenocarcinoma shows 2 late-stage studies (Phase 3 and Phase 4 combined) alongside 28 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Esophageal Adenocarcinoma is led by Mayo Clinic with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 44 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Esophageal Adenocarcinoma?
PlainTrial tracks 44 US clinical trials for Esophageal Adenocarcinoma, of which 27 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Esophageal Adenocarcinoma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.